Reed Smith Advised Webster Equity Partners On Sale Of CenExel To BayPine

Reed Smith advised Webster Equity Partners on sale of CenExel to BayPine

Reed Smith advised Webster Equity Partners and its portfolio company, CenExel Clinical Research, on a definitive agreement to sell CenExel to investment firm BayPine.

The terms of the transaction remain confidential and the deal is subject to customary closing conditions and regulatory approvals.

CenExel is a leading clinical trial site network specializing on complex therapeutic areas. The transaction allows the company to advance its mission of providing state-of-the-art clinical research centers to the nation’s leading pharmaceutical companies. Webster Equity Partners will retain a minority stake in the company after the transaction closes.

Reed Smith worked with Webster Equity Partners as health care counsel on its initial investment in CenExel, and was honored to work with the company as it expanded its services.

The Reed Smith deal team was led by partner Nicole Aiken-Shaban (Partner), including Carol Loepere (Partner), Sarah Thompson Schick (Counsel), Taber Reuter (Associate) and Seb Dugmeoglu (Associate).

Click to know more about Reed Smith

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.